trial

Efficacy of Lu 31-130 in Patients With Schizophrenia

NCTId NCT00770744
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 93 (actual)
Sponsored by H. Lundbeck A/S
Primary completion 2009-10
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
93 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-09
Primary completion
2009-10
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
ZicronapineOlanzapine

Sponsors

H. Lundbeck A/SLead Sponsor

Sites

21 total
České Budějovice, CzechiaLitoměřice, CzechiaLnáře, CzechiaOlomouc, CzechiaOlomouc, CzechiaPrague, CzechiaClermont-Ferrand, FranceDole, FranceJonzac, FranceHong Kong, Hong KongBangli, IndonesiaJakarta, Indonesia

Linked catalysts

1
Efficacy of Lu 31-130 in Patients With Schizophrenia — primary completion2009-10

Facts & assertions

4 sourced
Enrollment
93
Phase
PHASE2
Primary Completion Date
2009-10
Status
COMPLETED
relationships
The graph out of here
drug
Zicronapine
drug
Olanzapine
drug
lead_sponsor
H. Lundbeck A/S
company
indication
Schizophrenia
indication
Schizophrenia
indication